Takeda Goes Global With $13.7B Nycomed Deal

Law360, New York (May 19, 2011, 12:46 PM EDT) -- Takeda Pharmaceutical Co. Ltd. pushed into Europe on Thursday with the purchase of Swiss drugmaker Nycomed A/S for $13.7 billion in cash, giving the Japanese buyer access to Nycomed’s $4 billion in annual revenue.

The deal is part of the buyer's self-described "Transformation into a New Takeda" plan, announced May 11, in which it said it would accelerate its efforts to go global. Takeda's plan is geared toward replacing revenues the company will lose from the expiration of its patent for the Actos diabetes drug, which...
To view the full article, register now.